Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a significant breakthrough in its influenza Artificial Intelligence programme with CytoReason. Poolbeg has been working with CytoReason since March 2022.
The unique disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analysed using CytoReason’s industry-leading AI-led platform. The analysis has led to the discovery of multiple novel drug targets for the treatment of influenza.
Identification of drug targets from this unique data-set has previously been successful as p38 MAP Kinase, inhibited by POLB 001, was identified as a driver of severe influenza but this required manual analysis that took several years.
However, through the utilisation of CytoReason’s cutting-edge AI technology, Poolbeg has now identified multiple novel drug targets in just 15 months. Moreover, CytoReason’s analysis independently confirmed the significance of the p38 MAP kinase pathway in influenza, providing further validation for Poolbeg’s POLB 001 programme.
Our collaboration with CytoReason has put Poolbeg at the forefront of AI drug discovery
- Jeremy Skillington, CEO of Poolbeg Pharma
The company is actively exploring the most effective way to further develop the novel drug targets in order to generate value and looks forward to updating shareholders about the progress of this programme in due course.
This marks Poolbeg’s second successful AI Programme, following the identification of potential new drug candidates for Respiratory Syncytial Virus (RSV) announced in December 2022.
Jeremy Skillington, CEO of Poolbeg Pharma, commented: “Our collaboration with CytoReason has put Poolbeg at the forefront of AI drug discovery. CytoReason’s deep interrogation of the uniquely rich data derived from human challenge trials has deepened our knowledge of influenza, resulting in the identification of multiple novel influenza drug targets. There is a significant unmet need for new and better treatments for vulnerable patients with influenza and this is a major milestone in the delivery of new therapies that can improve patient outcomes and global health.”
David Harel, CEO of CytoReason, said: "Once again, we’re pleased to see that leveraging CytoReason’s computational disease models to extract insights from Poolbeg’s unique human challenge data can optimise the target discovery process. More importantly, these impressive results would not be possible without the commitment, transparency, and reciprocity of both teams.”
